Project 1 - Microglial activation in DNRAb-mediated brain pathology in mice

NIH RePORTER · NIH · P01 · $931,639 · view on reporter.nih.gov ↗

Abstract

Project 1: Abstract We have shown that DNRAb, antibodies that cross-react with DNA and N-methyl D-aspartate receptor, cause cognitive impairment when they penetrate the hippocampus. The neural injury proceeds in two stages. First, there is excitotoxic neuronal death; second, there is microglial activation and dendritic loss in surviving neurons. Microglial suppression by angiotensin converting enzyme (ACE) inhibition restores neuronal integrity and cognitive function. We propose now to study the mechanism of microglial activation and dendritic loss and the mechanism of action of ACE inhibition. These studies have the potential to suggest additional therapeutic targets for ameliorating cognitive impairment in neuropsychiatric lupus.

Key facts

NIH application ID
10024601
Project number
2P01AI073693-11A1
Recipient
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Principal Investigator
BRUCE Thomas VOLPE
Activity code
P01
Funding institute
NIH
Fiscal year
2020
Award amount
$931,639
Award type
2
Project period
2008-08-01 → 2025-06-30